SCHEMBL7147806

SCHEMBL7147806

C=CCNc1nccc(-n2c(NCC=C)nc3ccccc32)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 1/20 0.44
MKNK1 Q9BUB5 10/20 0.43
MKNK2 Q9HBH9 8/20 0.43
PIK3CA P42336 1/20 0.41
MTOR P42345 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
TSHR P16473 1/20 0.40
MAPK10 P53779 3/20 0.38
SUMO3 P55854 1/20 0.38
SUMO2 P61956 1/20 0.38
SUMO1 P63165 1/20 0.38
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7103831 0.88 MKNK1 (0.41) LCKMKNK1MKNK2PIK3CAMTOR
SCHEMBL7100179 0.84 MAPK10 (0.41) LCKMKNK1MKNK2MAPK10SUMO3
SCHEMBL7148377 0.81 TP53 (0.41) LCKMKNK1MKNK2CYP1A2CYP3A4
SCHEMBL7097114 0.80 LCK (0.38) LCKMKNK1MKNK2MAPK10SUMO3
SCHEMBL7152631 0.80 LCK (0.40) LCKMKNK1MKNK2TSHRMAPK10
SCHEMBL7145870 0.79 LCK (0.70) LCKMKNK1MKNK2
SCHEMBL7097579 0.79 MAPK10 (0.40) LCKMKNK1MKNK2MAPK10
SCHEMBL7147218 0.79 MAPK10 (0.38) LCKMKNK1MKNK2MAPK10SUMO3
SCHEMBL7147406 0.78 MAPK13 (0.41) LCKMKNK1MKNK2MAPK10RAB9A
SCHEMBL9271690 0.67 FDPS (0.49) TSHRSUMO3SUMO2SUMO1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1206265-B1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2003-11-12 EP disclosed
US-6498165-B1 PYRIMIDINE COMPOUNDS; PROPHYLAXIS AND TREATMENT OF SUCH AS IMMUNE DISEASES, HYPERPROLIFERATIVE DISORDERS, CANCER, ANGIOGENSIS, ATHEROSCELEROSIS, GRAFT REJECTION, RHEUMATOID ARTHRITIS, PSORIASIS MERCK & CO., INC. 2002-12-24 US disclosed
EP-1194152-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-11-06 EP disclosed
EP-1206260-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-10-30 EP disclosed
EP-1206265-A4 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO INC (US) 2002-08-07 EP disclosed
EP-1206265-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP disclosed
EP-1206260-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-05-22 EP disclosed
EP-1194152-A1 SRC KINASE INHIBITOR COMPOUNDS Merck & Co., Inc. (US) 2002-04-10 EP disclosed
US-6329380-B1 PYRIMIDINE BENZIMIDIZAZOLE, PYRIMIDINEIMIDAZOLE OR PYRIDINE IMIDAZOLE COMPOUNDS FOR ANTICANCER AGENTS OR ATHEROSCLEROSIS MERCK & CO., INC. 2001-12-11 US disclosed
US-6316444-B1 SRC kinase inhibitor compounds MERCK & CO., INC. 2001-11-13 US disclosed
WO-2001000213-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed
WO-2001000207-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed
WO-2001000214-A1 SRC KINASE INHIBITOR COMPOUNDS MERCK & CO., INC. (US) 2001-01-04 WO disclosed